Evidence Level
Emerging
Phenylpiracetam was developed at the Russian Academy of Sciences in the 1980s and has been studied primarily in Russian clinical literature. Savchenko et al. (2005) demonstrated cognitive improvements in stroke patients. Malykh and Sadaie (2010) reviewed the racetam family and noted phenylpiracetam's superior potency and additional psychostimulant properties. Its WADA ban validates its performance-enhancing effects. Western clinical trial data is limited, and most evidence comes from Russian research and widespread anecdotal use in the nootropics community.